Dana-Farber Cancer Institute researchers receive 2021 Movember-Distinguished Gentleman's Ride-Prostate Cancer Foundation Challenge Award
Dana-Farber Cancer Institute researchers are recipients of a new Movember - Prostate Cancer Foundation (PCF) Challenge Award. The $1 million award aims to support ambitious team science with the potential to develop new treatments for metastatic prostate cancer. Dana-Farber's Matthew Freedman, MD, is principal investigator. Other Dana-Farber team members include Mark Pomerantz, MD, and Sylvan Baca, MD, PhD.
There are currently no curative treatment options for prostate cancer that has progressed to a metastatic, treatment-resistant state. Freedman and the team have identified a set of gene transcription regulators that control this progression. They are testing whether these regulators may serve as promising targets for developing new treatments to prevent progression to advanced, lethal prostate cancer. The team is also developing a prostate cancer research resource, which will help other investigators uncover novel biology and treatment opportunities for prostate cancer patients.
The Movember - PCF Challenge Awards, totaling $2 million, are granted to teams at some of the world's leading cancer research institutions to support cross-disciplinary pioneering research toward the goal of finding cures for prostate cancer. Of these funds, $1.3 million was raised from the 2020 Movember U.S. Campaign and nearly $200,000 came from the 2020 Distinguished Gentleman's Ride.
2021 Movember-Distinguished Gentleman's Ride-PCF Challenge Award
Principal Investigator: Matthew Freedman, MD (Dana-Farber Cancer Institute, Harvard University).
Co-Investigators: Mark Pomerantz, MD (Dana-Farber Cancer Institute), Wilbert Zwart, PhD (The Netherlands Cancer Institute), Sylvan Baca, MD, PhD (Dana-Farber Cancer Institute), Tesa Severson, PhD (Netherlands Cancer Institute).
Project Title: Leveraging Epigenomics to Target Acquired Vulnerabilities in Treatment-Resistant Prostate Cancer
